BELFOR
22.6.2022 17:39:12 CEST | Business Wire | Pressemeddelelse
BELFOR, verdens største skadeservicevirksomhed og SSG, førende på det skandinaviske marked inden for skadesanering og genopbygning, har slået sig sammen for at styrke vores kundeservice i Danmark, Norge og Sverige.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20220622005634/da/
BELFOR har nu mere end 12.500 medarbejdere og 500+ lokationer i hele verden. Vi dækker alle led, når det kommer til genopbygning efter en skade. Vi vurderer skaden, igangsætter nødvendige foranstaltninger, og vi sørger for renovering og genopbygning, uanset skadens omfang.
SSG Group tilbyder bl.a. skadeservice, renovering og genopbygning og har 980 medarbejdere, fordelt på 57 lokationer i Danmark, Sverige og Norge.
"Med SSG udvider vi vores dygtige og erfarne teams med gode folk, øger vores servicekapacitet og optimerer vores responstider for vores nationale og internationale kunder", udtaler Elvir Kolak, CEO for BELFOR Europe.
"Denne transaktion betyder et enormt løft for vores organisationer i Danmark, Norge og Sverige. Ved at kombinere BELFORS tekniske kompetencer med vores serviceportefølje åbner vi for nye udviklingsmuligheder for vores medarbejdere", tilføjer Carsten Fensholt, CEO for SSG Group.
"Vi er glade for at byde SSG velkommen i BELFOR-familien, og vi glæder os til at medvirke til deres fremtidige vækst. SSG beskæftiger fantastiske medarbejdere og har stort fokus på kunderne – og er derfor et perfekt match for os! Vi er stolte over at få dem ombord. Hos BELFOR er vores vækstplaner ambitiøse, og vi leder aktivt efter gode virksomheder, der kan tilslutte sig BELFOR-familien – både i Skandinavien og resten af Europa", afslutter Sheldon Yellen, global CEO hos BELFOR.
Fremover vil BELFOR være Danmarks førende skadeservicevirksomhed med tilføjelsen af 650 nye medarbejdere. Opkøbet af SSG er et stort skridt på vejen mod en større tilstedeværelse i Skandinavien, som startede med erhvervelsen af det danske skadeservicefirma, Røsva, efterfulgt af Rølund i 2021.
OM BELFOR
BELFOR er førende på det globale marked inden for skadeservice. Med mere end 40 års erfaring kan vi hos BELFOR tilbyde at hjælpe dig igennem hele dit skadesforløb, lige fra vurdering af skaden, til renovering og genopbygning. Det betyder bl.a., at vi er den foretrukne partner både for forsikringsselskaber samt kommercielle og private kunder. Med SSG under fanen har BELFOR nu mere end 12.500 ansatte og 500 lokationer i 57 lande. Vi er klar til at hjælpe vores kunder 24 timer i døgnet, 365 dage om året, uanset hvor store og komplekse skaderne er.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220622005634/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum